Catherine Olivier

University of Leeds

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Collaborators (6)

Samuel Smith

Professor of Behavioural Oncology

University of Leeds

UNITED KINGDOM

View details

Annamaria Brioli

Consultant, Head of the Plasma Cell Dyscrasias and Multiple Myeloma Clinic and Translational Research Program

Medizinische Hochschule Hannover

GERMANY

View details

Mark Drayson

Professor Clinical Immunodiagnostics

University of Birmingham

UNITED KINGDOM

View details

Michelle Collinson

Associate Professor in Clinical Trials

University of Leeds

UNITED KINGDOM

View details

Kamaraj Karunanithi

UNITED KINGDOM

View details

Matthew W. Jenner

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Catherine Olivier

Research Interests

Explore related searches

Contact this professor

Articles (10)

Risk adapted therapy for newly diagnosed multiple myeloma delivered through local cytogenetic laboratories in a National Clinical Trial: UKMRA RADAR study

Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients

MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation

Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial

OA-19 Marrow Immune Features Are Most Informative of Early MRD Negative Treatment Response in Newly Diagnosed TE Patients: Insights from the UKMRA Phase 3 RADAR Study

OA-59 Proteasome Inhibitor-Augmented Salvage Autologous Stem Cell Transplantation for First Relapse Management in Relapsed Multiple Myeloma

P-235 Isatuximab as Post-ASCT Therapy in MRDpositive Patients Augments CD8 Effector T Cell Differentiation: Insights from the UKMRA Phase 3 RADAR Study

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open-label, randomised, phase III trial

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial

Acceptance and Commitment Therapy to support medication decision-making and quality of life in women with breast cancer: protocol for a pilot randomised controlled trial

Collaborators (6)

Samuel Smith

Annamaria Brioli

Mark Drayson

Michelle Collinson

Kamaraj Karunanithi

Matthew W. Jenner

Make your next move.